Heilmittel Group is proud to announce the upcoming European launch of PuraMouv®, a next-generation topical balm combining Ultra-Pure Synthetic CBD with Glucosamine for advanced muscle and joint relief. The official launch is scheduled for October 2025 across selected European markets.
PuraMouv® has been developed with the same scientific precision that defines our Cebedi®brand, offering:
- Ultra-Pure Synthetic CBD – ensuring pharmaceutical-grade consistency, purity, and safety compared to plant-derived CBD.
- Glucosamine – clinically recognized for supporting joint comfort and mobility.
- A synergistic formulation designed to deliver both soothing relief for muscles and long-term support for joint health.
Why PuraMouv®?
Unlike traditional balms, PuraMouv® combines the anti-inflammatory and recovery potential of synthetic CBD with structural support from Glucosamine, addressing both the discomfort and underlying joint stresses. Manufactured under GMP-certified conditions in Europe, the balm ensures premium quality, safety, and efficacy.
PuraMouv® will complement the growing Cebedi® line of Ultra-Pure CBD supplements, strengthening Heilmittel Group’s positioning as a global innovator in cannabinoid-based wellness solutions. With its European launch, PuraMouv® marks the Group’s commitment to delivering cutting-edge, science-backed formulations that meet the diverse needs of modern consumers.